Heart failure drug samtasu put to the test in 1,600-Patient safety survey
NCT ID NCT05712746
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study monitors the safety of the intravenous drug Samtasu (tolvaptan sodium phosphate) in people with heart failure who have fluid overload. Researchers will track side effects, including serious events and off-label use, in about 1,600 patients. The goal is to confirm the drug's safety in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Samtasu (tolvaptan sodium phosphate)
What this could lead to
If this study shows Samtasu is safe in a broad group of heart failure patients, it could support its continued use to help remove excess fluid and ease symptoms.
What could go wrong
This is an observational safety study, not a test of effectiveness. It may reveal unexpected side effects or find that the drug does not work well in certain patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pharmacovigilance Department
Osaka, 540-0021, Japan